Sutro Biopharma
STRO
120 hedge funds and large institutions have $252M invested in Sutro Biopharma in 2023 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 45 increasing their positions, 37 reducing their positions, and 13 closing their positions.
440% more call options, than puts
Call options by funds: $27K | Put options by funds: $5K
38% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 13
22% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 37
4% more funds holding
Funds holding: 115 → 120 (+5)
2% more capital invested
Capital invested by funds: $248M → $252M (+$4.09M)
0.35% less ownership
Funds ownership: 9.31% → 8.95% (-0.35%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$4.9M |
| 2 |
Verition Fund Management
Greenwich,
Connecticut
|
+$3.99M |
| 3 |
EP
Eversept Partners
New York
|
+$3.72M |
| 4 |
Millennium Management
New York
|
+$3.05M |
| 5 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$2.98M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$9.1M |
| 2 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
-$4.96M |
| 3 |
Goldman Sachs
New York
|
-$2M |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
-$1.55M |
| 5 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$1.55M |
STRO Hedge Fund Activity: Q2 2023 in Review
120 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Sutro Biopharma (STRO) for Q2 2023, worth a combined $252M — up 1.7% from $248M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new STRO positions and 13 closed out — a net gain of 5 holders — while 45 added to existing stakes and 37 trimmed.
The largest buyer was BlackRock, adding an estimated $4.9M. The largest seller was State Street, cutting an estimated $9.1M.
- 120 institutional investors held Sutro Biopharma (STRO) as of Q2 2023, up from 115 in Q1 2023.
- Funds reported $252M of Sutro Biopharma stock for Q2 2023, up 1.7% quarter-over-quarter.
- 18 funds opened new Sutro Biopharma positions in Q2 2023 and 13 closed out, a net change of +5 holders.
- The largest Sutro Biopharma buyer in Q2 2023 was BlackRock, an estimated $4.9M added.
- The largest Sutro Biopharma seller in Q2 2023 was State Street, an estimated $9.1M sold.
Based on aggregated 13F filings for Q2 2023.